Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-14
2007-08-14
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S537000
Reexamination Certificate
active
11193089
ABSTRACT:
The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.
REFERENCES:
patent: 4137322 (1979-01-01), Endo et al.
patent: 4681893 (1987-07-01), Roth
patent: 5003080 (1991-03-01), Butler et al.
patent: 5273995 (1993-12-01), Roth
patent: 5298627 (1994-03-01), Butler et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5969156 (1999-10-01), Briggs et al.
patent: 6087511 (2000-07-01), Lin et al.
patent: 6121461 (2000-09-01), McKenzie
patent: 6476235 (2002-11-01), Butler et al.
patent: 6528661 (2003-03-01), Niddam et al.
patent: 6600051 (2003-07-01), Tully
patent: 6605636 (2003-08-01), Aronhime et al.
patent: 6605728 (2003-08-01), O'Connell et al.
patent: 6605729 (2003-08-01), Byrn et al.
patent: 7030151 (2006-04-01), Ker{hacek over (c)} et al.
patent: 7074818 (2006-07-01), Manne et al.
patent: 2002/0099224 (2002-07-01), Niddam et al.
patent: 2002/0115709 (2002-08-01), Aronhime et al.
patent: 2003/0114686 (2003-06-01), Van der Schaaf et al.
patent: 2003/0212279 (2003-11-01), Tessler et al.
patent: 2003/0216584 (2003-11-01), Aronhime et al.
patent: 2004/0054193 (2004-03-01), Byrn et al.
patent: 2004/0077708 (2004-04-01), Grahek et al.
patent: 2004/0106670 (2004-06-01), Blatter et al.
patent: 2004/0220255 (2004-11-01), Van Der Schaaf et al.
patent: 2004/0242899 (2004-12-01), Reddy et al.
patent: 2005/0209306 (2005-09-01), Jegorov et al.
patent: 2006/0063826 (2006-03-01), Lifshitz-Liron et al.
patent: 2006/0122403 (2006-06-01), Suri et al.
patent: WO 97/03960 (1996-07-01), None
patent: WO 97/03958 (1997-02-01), None
patent: WO 97/03959 (1997-02-01), None
patent: WO 00/71116 (2000-11-01), None
patent: WO 02/057228 (2001-01-01), None
patent: WO 01/28999 (2001-04-01), None
patent: WO 01/36384 (2001-05-01), None
patent: WO 01/42209 (2001-06-01), None
patent: WO 01/44180 (2001-06-01), None
patent: WO 01/44181 (2001-06-01), None
patent: WO 02/41834 (2002-05-01), None
patent: WO 02/43732 (2002-06-01), None
patent: WO 02/051804 (2002-07-01), None
patent: WO 02/057229 (2002-07-01), None
patent: WO 02/059087 (2002-08-01), None
patent: WO 02/083637 (2002-10-01), None
patent: WO 02/083638 (2002-10-01), None
patent: WO 03/004470 (2003-01-01), None
patent: WO 03/011826 (2003-02-01), None
patent: WO 03/016317 (2003-02-01), None
patent: WO 03/018547 (2003-03-01), None
patent: WO 03/050085 (2003-06-01), None
patent: WO 03/070702 (2003-08-01), None
patent: WO 2004/022053 (2004-03-01), None
patent: WO 2004/050618 (2004-06-01), None
Thomas M.A. Bocan et al. “Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation”, Atherosclerosis 111 (1994) pp. 127-142.
Bang-Chi Chen et al., “Synthesis of Deuterium-Labeled Atorvastatin and its Metabolites for Use as Internal Standards in a LC/MS/MS Method Developed for Quantitation of the Drug and its Metabolities in Human Serum,” Journal of Labelled Compounds and Radiopharmaceuticals 43 (2000) pp. 261-270.
K.L. Baumann et al., “Convergent Synthesis of Cl-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase,” Tetrahedron Letters, vol. 33, No. 17 (1992) pp. 2283-2284.
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. (1996) pp. 879-881.
Declaration Under Rule 132 by Thomas M. A. Bocan, dated Dec. 2, 1998, filed in U.S. Appl. No. 08/945,812; 2 pages.
Declaration Under Rule 132 by Stephen R. Byrn, dated Nov. 25, 1998, filed in U.S. Appl. No. 08/945,812; 3 pages.
Rouhi, Chem. & Eng. News, Feb. 24, 2003, pp. 32-35.
Cheronis, Semimicro Experimental Organic Chemistry, pp. 31-49, 1958.
Haleblian & Crone, 1969. J. Pharm. Sci.58:911-929.
David J. W. Grant, Theory and Origin of Polymorphism, in Drugs of the Pharmaceutical Sciences, vol. 95, Polymorphism in Pharmaceutical Solids, Chapter 1, (Harry G. Brittain ed., 1999).
G. Michael Wall, “Pharmaceutical Applications of Drug Crystal Studies”, Pharmaceutical Manufacturing (Feb. 1986) pp. 33-42.
U.S. Pharmacopia #23, p. 1843, 941 X-Ray Diffraction, 1995.
Pending U.S. Appl. No. 10/994,142, Nov. 19, 2004, Aronhime et al.
McCrone W.C., “Polymorphism”, Physics and Chemistry of the Organic Solid State, vol. 2, 1965, pp. 725-767.
Caira M.R., “Crystalline Polymorphism of Organic Compounds” Topics in Current Chemistry, Springer, Berlin, DE, vol. 198, 1998, pp. 163-208.
Graul A., et al., “Atorvastatin Calcium” Drugs of the Future, Barcelona, ES, vol. 22, No. 9, 1997, pp. 956-968.
Guillory, J.K.: “in Polymorphism in Pharmaceutical Solids (Brittain, H.G., ed.)”, 1999, Marcel Dekker, Inc., New York, Basel, pp. 183-226.
Hancock B.C., et al., “Characteristics and Significance of the Amorphous State in Pharmaceutical Systems”, Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, U.S., vol. 86, No. 1, Jan. 1997, pp. 1-12.
Concise Encyclopedia Chem. (1993), Walter deGruyter, Berlin, NY.
Aronhime Judith
Hasson Nir
Lifshitz-Liron Revital
Maidan-Hanoch Dalia
Tessler Limor
Kenyon & Kenyon LLP
Powers Fiona T.
Teva Pharmaceutical Industries Ltd.
LandOfFree
Crystal forms of atorvastatin hemi-calcium and processes for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystal forms of atorvastatin hemi-calcium and processes for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystal forms of atorvastatin hemi-calcium and processes for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3850452